Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00006392 · ClinicalTrials.gov registry record · Phase 3
S0000 Selenium and Vitamin E in Preventing Prostate Cancer
A Phase 3 study of Prostate Cancer, sponsored by SWOG Cancer Research Network.
- Completed
- Registry status
- Phase 3
- Development phase
- 35,533
- Enrollment target
- 13
- Study locations
NCT00006392: Completed Phase 3 study of Prostate Cancer, sponsored by SWOG Cancer Research Network.
NCT00006392 is a Phase 3 study of Prostate Cancer that has completed, run by SWOG Cancer Research Network. The registered enrollment target is 35,533 participants, above the 560-participant average among 735 other Prostate Cancer trials with a reported enrollment target (6245% higher). The trial reports 13 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00006392, a Phase 3 study of Prostate Cancer, has completed, sponsored by SWOG Cancer Research Network.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 35,533 participants
- Enrollment target
- 13
- Study locations
Study Summary
RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development of cancer. It is not yet known which regimen of selenium and/or vitamin E may be more effective in preventing prostate cancer. PURPOSE: Randomized phase III trial to determine the effectiveness of selenium and vitamin E, either alone or together, in preventing prostate cancer.
Primary Outcome
Participants are seen at the study site every six month for an update of medical events. Prostate cancer diagnosis is based on participant report followed by the submission of a pathologic sample to central pathology review for confirmation.
Conditions Studied
Interventions
- DRUG Vitamin E
- DRUG Selenium
- OTHER Vitamin E placebo
- OTHER selenium placebo
Study Locations (13)
Illinois
- Robert H. Lurie Comprehensive Cancer Center at Northwestern University - Chicago
- Midwest Center for Hematology/Oncology - Joliet
- Cardinal Bernardin Cancer Center at Loyola University Medical Center - Maywood
Ohio
- Good Samaritan Hospital Cancer Treatment Center - Cincinnati
- Bethesda North Hospital - Cincinnati
- Tod Children's Hospital - Youngstown
Pennsylvania
- Geisinger Medical Center - Danville
- Geisinger Medical Group - Scenery Park - State College
- Frank M. and Dorothea Henry Cancer Center at Geisinger Wyoming Valley Medical Center - Wilkes-Barre
Missouri
- CCOP - Cancer Research for the Ozarks - Springfield
- St. John's Regional Health Center - Springfield
Oklahoma
- LaFortune Cancer Center at St. John Medical Center - Tulsa
Tennessee
- U.T. Cancer Institute at University of Tennessee Medical Center - Knoxville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35,533 participants |
| Start Date | 2001-07 |
| Est. Completion | 2012-09 |
| Phase | Phase 3 |
What the finished NCT00006392 record still lists
NCT00006392 is an interventional study that assigns participants to a tested intervention. Its 35,533 participants enrollment target places it among the larger protocols in the corpus, above the 560-participant average among 735 other Prostate Cancer trials with a reported enrollment target (6245% higher).
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 4 interventions - of which Vitamin E is the first listed.
NCT00006392 lists 13 locations in 6 states (Illinois, Ohio, Pennsylvania).
Frequently Asked Questions
What is clinical trial NCT00006392 about?
NCT00006392 is a clinical study titled "S0000 Selenium and Vitamin E in Preventing Prostate Cancer". RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development of cancer. It is not yet known which regimen of selenium and/or vitamin E may be more effective in preventing prostate cancer. PURPOSE: Randomized phase III trial to determine the effectiveness of selen...
What is the current status of trial NCT00006392?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 35,533 participants. The study started on 2001-07. Estimated completion is 2012-09.
What conditions does trial NCT00006392 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT00006392?
The interventions under investigation include: Vitamin E (DRUG), Selenium (DRUG), Vitamin E placebo (OTHER), selenium placebo (OTHER).
Who is sponsoring clinical trial NCT00006392?
This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00006392 being conducted?
This trial has 13 study locations across Illinois, Missouri, Ohio, Oklahoma, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00006392's enrollment target sits among peer trials
35,533 3rd of 735 higher than 733 of 735 other Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer
RECRUITING · Phase 3
-
PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.
RECRUITING · Phase 3
-
Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment
RECRUITING · Phase 3
-
Robotic Opioid-free Prostatectomy Enhanced Strategy (ROPES)
RECRUITING · Phase 3
-
SAFE Nerve Sparing Guided by Micro-ultrasound (MUS)
RECRUITING · Phase 3
-
Adjuvant Curcumin to Assess Recurrence Free Survival in Patients Who Have Had a Radical Prostatectomy
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03262259 · 36,000 participants · NA
Evaluation of Global Smart Drinking Goals Initiative
- NCT02225301 · 35,000 participants · NA
iLookOut for Child Abuse -Online Learning Module for Early Childcare Providers
- NCT07150923 · 36,503 participants · NA
Supraglottic Airway for Resuscitation Trial
- NCT03720613 · 34,532 participants
Risk of Major Adverse Cardiovascular Events for Naldemedine & Other Medications for Opioid Induced Constipation
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia